The actinomycete Microbispora sp. ATCC‐PTA‐5024 produces the lantibiotic NAI-107, which has been attracting the attention as a potential drug candidate. In fact, NAI-107 is active against vancomycin resistant Gram-positive pathogens and its in vivo efficacy was confirmed using animal models. Although NAI-107 has a high potential as a therapeutic drug, the producer strain is only poorly characterized. Thus, high throughput studies may give some insights in order to investigate biochemical capability, metabolic pathways and regulation of NAI-107 production. A comprehensive proteomic-based study was performed to unravel changes in global protein expression.
MICROBISPORA sp. ATCC - PTA - 5024 PROTEOME ANALYSIS : UNRAVELING THE MOLECULAR PHYSIOLOGY OF LANTIBIOTIC PRODUCTION
G Renzone;A Scaloni;
2013
Abstract
The actinomycete Microbispora sp. ATCC‐PTA‐5024 produces the lantibiotic NAI-107, which has been attracting the attention as a potential drug candidate. In fact, NAI-107 is active against vancomycin resistant Gram-positive pathogens and its in vivo efficacy was confirmed using animal models. Although NAI-107 has a high potential as a therapeutic drug, the producer strain is only poorly characterized. Thus, high throughput studies may give some insights in order to investigate biochemical capability, metabolic pathways and regulation of NAI-107 production. A comprehensive proteomic-based study was performed to unravel changes in global protein expression.| File | Dimensione | Formato | |
|---|---|---|---|
|
GIMXI0160_GGallo.pdf
accesso aperto
Descrizione: 12th International Symposium on the Genetics of Industrial Microorganisms (GIM-2013)
Tipologia:
Abstract
Licenza:
Altro tipo di licenza
Dimensione
123.55 kB
Formato
Adobe PDF
|
123.55 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
